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Summary
Purpose: To evaluate the efficacy and tolerability of Levetiracetam (LEV) in a large
pediatric cohort with drug-resistant epilepsy from a prospective multicenter obser-
vational study.
Methods: We report the results of a multicenter observational survey of a cohort of
285 pediatric patients (mean: 9.9 years, range: 0; 6—17; 11) with refractory general-
ized and focal epilepsy who received Levetiracetam as an add-on open label treat-
ment trial. The average duration of epilepsy was 6.0 years and the patients were
treated with a mean of 7.0 antiepileptic drugs (AED) before LEV was introduced.
Results: No serious persistent adverse events were reported. Reversible colitis and an
apnoea syndrome in a child with phosphorylase-A-kinase-deficiency were noted. Mild* Corresponding author. Tel.: +49 521 144 4607; fax: +49 521 144 4562.
E-mail address: ingrid.tuxhorn@evkb.de (I. Tuxhorn).
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Levetiracetam in 285 children 477to moderate side effects were reported in 128 patients (44.9%), consisting most
frequently of somnolence (23.9%), general behavioral changes (15.4%), aggression
(10.5%) and sleep disturbances (3.2%).
In 209 patients, efficacy was analyzed over a treatment period of at least 12 weeks
compared to a baseline of 2 weeks. Thirteen patients (6.2%) became seizure free, 39
(18.7%) responded with a seizure reduction of more than 50% following introduction of
LEV. No response to LEV was reported in 65.1% (n = 136). A decrease of initial
treatment effect was seen in 37 patients (17.8%) while in 6.7% the seizure frequency
doubled to the baseline (n = 14). In seven patients (3.3%), the effect of LEV on seizure
frequency could not be evaluated. A positive psychotropic effect was observed in 18
patients (8.6%).
Mental retardation was associated with poor response and associated with more
side effects and earlier discontinuation of LEV therapy.
Conclusion: LEV is a well-tolerated new AED that may effectively improve seizure
control as an add-on drug in resistant epilepsy in childhood with good tolerability.
However, neurologically handicapped children appear at increased risk for reversible
neurocognitive side effects and have a poorer treatment response.
# 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
In the last 10 years, a substantial number of new
antiepileptic drugs (AED) have been developed and
introduced into clinical epilepsy treatment which
include Felbamate (FBM), Gabapentin (GBP), Lamo-
trigine (LTG), Oxcarbazepine (OCBZ), Tiagabine
(TGB), Topiramate (TPM) and Vigabatrin (VGB). All
of these new AEDs were first tested in adults and
subsequently many of them have proven to be effi-
cacious and safe in children as well.
Levetiracetam (LEV) is a new AED which was well
tolerated, safe and efficacious in several phase-III-
LEV studies of adult patients.1—3 It has a favourable
pharmacological profile: almost complete absorb-
tion after oral administration, linear pharmacoki-
netics, low-protein binding under 10% and no
significant drug interactions appear to take place.
Data on the pharmacokinetics in children appear to
be similar to those reported in adult patients.4 In
addition, the first clinical studies suggest that LEV
may be a valuable drug in the treatment of epilepsy
in children; however, the available data to date are
either retrospective studies or prospective studies
with an open label design in a small number of
patients.5
In November 2000, LEV was approved as an antic-
onvulsant for add-on use in Germany to treat adults
with partial seizures with or without secondary
generalization. Since then it has also been used in
individual cases in children with refractory epilepsy.
A pediatric study group was coordinated in the year
2000 with 19 child neurology departments partici-
pating throughout Germany. The main objective of
this study group was to document and evaluate first
clinical experiences with LEV in a large group ofpediatric patients. A questionnaire was compiled
comprising a number of clinical parameters to ana-
lyse effectivity and tolerability of the drug. Wewere
able to survey and document the clinical response
with regard to seizure control and side effects and in
addition define a number of predictive variables for
both in a large group of over 200 children and report
the results of this large prospective observational
study in this paper.
Methods
Patient population, data collection and
study design
From October 2000 to September 2002, data was
collected and documented in a standardized data
file from 19 pediatric neurology departments in Ger-
many for an open multicenter retrospective analysis
on children treated with LEV. The following clinical
variables were recorded: sex, age, AEDs used prior to
LEV, comorbidity, epilepsy classification, duration of
epilepsy, dose and titration of LEV, concomitant
therapies, response to therapy, duration of therapy,
side effects, laboratory findings, physical handicap
andmental retardation. Mental retardationwas clas-
sified according to ICD-10 F70.x to F73.x. There was
no titration protocol. Tolerability and side-effects
were assessed by documenting spontaneously
reported side-effects by the carers or by the child.
Patients younger than 18 years at the time of
treatment with LEV and an observational period of
at least 4 weeks were included in the analysis.
In a first step, we analysed the side effects and
tolerability of LEV.
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in controlling seizures. In this second analysis, we
included some patients with minor changes of the
baseline AEDs over a period of at least 2 weeks prior
to LEV-treatment and if the follow-up was at least 12
weeks. Outcome analysis was done on the clinical
information available from the last visit.
The primary efficacy outcome variable choosen
was a 50% responder rate, defined as a >50% reduc-
tion in seizure frequency during the evaluation
period compared to the baseline. In addition, the
participating neurologists were asked to grade the
outcome into one of the following categories
according to their clinical judgement: seizure free,
marked improvement, mild improvement, no
change, drug withdrawal due to side effects and
drug withdrawal due to worsening of seizures.
Statistical methods
Non-parametric tests (Fisher’s exact test, Mann—
Whitney test) and logistic regression analyses wereTable 1 Demographics.
Number Analysis of tolerability and sid
285
Sex (male/female) 137 boys, 128 girls, 20 n.d.
Age, median (range) 9.9 years, range: 0—17; 11 ye
Duration of epilepsy,
median (range)
6.0 years, range: 0—17.0 year
Cognitive impairment 22 (7.7%) no impairment
63 (22.1%) mild retardation
78 (27.4%) moderate retardat
115 (40.4%) severe retardatio
7 (2.5%) n.d.
Physical handicap 55 (19.3%) no impairment
84 (29.5%) mild retardation
53 (18.6%) moderate retardat
85 (29.8%) severe retardation
8 (2.8%) n.d.
Epilepsy syndrome 191 (67.0%) focal
49 (17.2%) generalized
45 (15.8%) focal and generaliz
Epilepsy etiology 42 (14.7%) idiopathic
58 (20.4%) cryptogenic
144 (50.5%) symptomatic
41 (14.4%) n.d.
Previous AED, median 7.0 (range = 0—20), 2 n.d.
Concomitant AED 8 (2.8%) none
87 (30.5%) one AED
128 (45.0%) two AED
56 (20.0%) two or more AED
6 (2.1%) n.d.
n.d.: no data, missing values.performed. If not mentioned otherwise, two-sided
p-values are given. SPSS computer package for Win-
dows (version 11.0; SPSS Inc., Chicago, IL, USA) was
used for statistical analyses.
Results
Patient characteristics
Of the total reports of 357 patients, 69 had to be
excluded because of insufficient data, a too short
observation period, age over 18 years, and prior LEV
treatment with inconclusive outcome in 3.
The data of the remaining 285 patients were
included for analysis of tolerability. The clinical
patient data (demographics, seizure types, epilepsy
syndromes, comorbidity, history of previous and
concomitant AEDs) of this group are reported in
Table 1.
The majority of patients (92.1%) had mental
retardation or a physical handicap (80.1%). Averagee effects Analysis of efficacy
209
100 boys, 93 girls, 16 n.d.
ars 9.7 years, range: 0.5—17.9 years
s 6.0 years, range: 0—17.0 years
16 (7.7%) no impairment
45 (21.5%) mild retardation
ion 52 (24.9%) moderate retardation
n 89 (42.5%) severe retardation
7 (3.3%) n.d.
42 (20.1%) no impairment
55 (26.3%) mild retardation
ion 42 (20.1%) moderate retardation
62 (29.7%) severe retardation
8 (3.8%) n.d.
139 (66,5%) focal
38 (18,2%) generalized
ed signs 32 (15,3%) focal and generalized signs
28 (13.4%) idiopathic
41 (19.6%) cryptogenic
110 (52.6%) symptomatic
30 (14.4%) n.d.
7.0 (range = 0—20), 1 n.d.
9 (4.3%) none
69 (33.0%) one AED
95 (45.5%) two AED
36 (17.2%) two or more AED
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Table 2 Side effects in 285 patients.
Number of
patients
Percent
Somnolence/fatigue 52 18.2
Somnolence only initially 16 5.6
Sleeping disturbance 9 3.1
Behavioral changes 44 15.4
Aggression 30 10.5
Altered mood 8 2.8
Loss of appetite 10 3.5
Vomiting 6 2.1
Tremor 6 2.1
Cognitive disturbance 5 1.8
Severe side effects
Hemorrhagic colitis 1 0.4
Apneas 1 0.4duration (standard deviation [S.D.]) of epilepsy
was 6.8  4.3 years. Before LEV treatment the
patients had received 6.8 (range 0—20) AED on
average and only 31 patients (11.0%) had received
fewer than 4 previous AED treatments. LEV treat-
ment was started as add-on treatment in most
patients and was given in monotherapy in only eight
patients (2.9%). The most prevalent comedication
was valproic acid (VPA) in 133 patients (47.7%),
followed by LTG in 44 patients (15.8%) and OCBZ
in 43 patients (15.4%).
Two hundred and nine of 285 patients (73%) had
no or only minor changes in concomitant AEDs in a
baseline period of at least 2 weeks prior to LEV
treatment and the follow up was at least 12 weeks.
These 209 patients were subject for further analysis
of the efficacy of LEV. The patient data of this group
are shown in Table 1. We included seven patients in
whom one of the concomitant AEDs was withdrawn
during LEV treatment but no change in seizure
frequency occurred during or after the drug with-
drawal.
Tolerability and side effects
Side effects were reported in 128 of 285 patients
(44.9%). After an average treatment duration of
10.5 (range: 1—50, median 6) weeks 49 patients
(17.2%) were taken off LEV because of the side
effects, although 10 of those had a good treatment
response (seizure reduction of more than 50%).
There was no relationship between titration sche-
dule and discontinuation due to side effects. With-
drawal due to side effects was more frequent in
patients who received LEV in monotherapy (5/10,
50.0%) compared to patients on comedication (44/
275, 16%; exact Fisher test, p = 0.017).
Only two serious adverse events which reversed
completely after drug withdrawal were reported: a
2-year-old girl developed bloody diarrhea and
vomiting one day after LEV was started. The diag-
nosis of hemorrhagic colitis without infectious
aetiology was made. LEV was stopped and the gas-
trointestinal symptoms reversed the following
day. Secondly, a severely retarded 8-year-old boy
with phosphorylase-A-kinase-deficiency developed
reversible apneas that ceased after LEV was
stopped.
The reported laboratory findings were within
normal range in all patients.
Mild side effects involving neuropsychological
functions were frequently reported which reversed
once the drug was withdrawn. Increased somno-
lence was the most common complaint (68/285,
23.9%), and was given as a reason for discontinuing
LEV treatment in three patients. In 16 patients,somnolence occurred transiently only in the titra-
tion phase. Mental retardation was a risk factor for
somnolence which was reported in 66 of 256 (25.8%;
Fisher’s exact test, p = 0.034) of the retarded
patients and only once in 22 patients without mental
retardation (4.5%).
Behavioral changes were the next most fre-
quently reported side effect and included aggres-
sive behavior in 44 patients (15.4%) and prompted
discontinuation of the drug in 23 cases (8.1%).
Behavioural changes were observed slightly more
frequently in patients with mental retardation (42/
256, 16.4% versus 1/22, 4.5%; Fisher’s exact test,
p = 0.11) and physical handicap (39/222 17.6% ver-
sus 4/55, 7.3%; Fisher’s exact test, p = 0.063) com-
pared to neurologically normal patients but the
differences did not reach statistic significance.
The most common behavioral adverse event was
aggression, which was seen in 30 patients (10.5%)
and was often severe. Two patients attacked others
violently, which they had never done before.
Aggression was observed more frequently in men-
tally retarded (28/256, 10.9% versus 1/22, 4.5%) and
physically handicapped patients (26/222, 11.7% ver-
sus 3/55, 5.5%), but again the differences were not
statistically significant (Fisher’s exact p > 0.1).
Severe mental retardation was however a signif-
icant risk factor for sleep disturbances which were
observed in nine patients (3.2%), all of whom were
severely retarded (exact Fisher test; p = 0.006).
Seven patients (2.5%) had a tremor and six of
these patients had a comedication with VPA.
For a summary of side effects see Table 2.
Rare side effects which are not listed were
weight gain (n = 1), weight loss (n = 2), hypersaliva-
tion (n = 2), ataxia (n = 2), abdominal pain (n = 2),
headache (n = 2), encopresis (n = 1), hyperpnoea in
480 J. Opp et al.
Table 3 Effect of LEVon seizure frequency in patients
on LEV therapy (total) and in patients still on LEV
therapy at last visit available (efficacy analysis).
Seizure frequency Number of
patients
included
in efficacy
analyses
Number
of patients
still on
LEV therapy
at last
visit available
Seizure free 13 (6.2%) 12 (5.7%)
Reduction of 76—99% 24 (11.5%) 20 (9.6%)
Reduction of 50—75% 15 (7.2%) 11 (5.3%)
No significant change 136 (65.1%) 24 (22.8%)
Increase of >100% 14 (6.7%) 0 (0.0%)
Effect on seizures could
not be evaluated
7 (3.3%) 3 (1.4%)
Total 209 (100%) 70 (33.5%)combination with Sulthiame (n = 1), constipation
(n = 1), itching (n = 1), and transitory rash (n = 1)
(Table 3).
Patients with ongoing LEV treatment at the last
visit (n = 115, 40.4%) were older (mean  S.D.:
10.3  4.4 years versus 8.8  4.7 years; Mann—
Whitney test, p = 0.009) than patients in whom
the drug had been withdrawn (n = 170, 59.6%) and
had a slightly longer duration of epilepsy
(mean  S.D.: 7.4  4.3 years versus 6.3  4.3
years, Mann—Whitney test, p = 0.048). Patients with
ongoing treatment were less mentally retarded than
patients in whom LEV had been withdrawn (Mann—
Whitney test, p = 0.012) and slightly less physically
handicapped (Mann—Whitney test, p = 0.089). The
comedication (number of AED) and number of AEDs
before add on LEV therapy was started was not
significantly associated with withdrawal of LEV.
Logistic regression analysis of multiple clinical
variables to look for predictive outcome variables
for responders, discontinuation of treatment and
risk factors for side effects demonstrated that men-
tal retardation (p = 0.006) was the only significant
predictor for discontinuation of LEV treatment. LEV
was withdrawn in 66.1% (76/115) of the severely
retarded, in 60.3% (47/78) of the moderately and
54% (29/62) of the mildly retarded children and only
in 36.5% (8/22) of the children without mental
retardation.
Withdrawal of LEV (n = 170) provoked seizures in
six patients (3.5%) which did not correlate with fast
or slower withdrawal. However, two patients devel-
oped de novo seizures in series (requiring ICU-care
and intravenous phenytoin in one patient) which had
never been observed before and were interpreted as
drug withdrawal seizures.
LEV was administered in a maximum dosage
(S.D.) of 47.7  21.8 mg/kg/day (range: 6—140 mg/kg/day), which was reached in 1—41 weeks
(median 3 weeks). Side effects occurred at a mean
dosage (S.D.) of 45.5  20.4 mg/kg/day. The titra-
tion speed and the maximum dosage were not sig-
nificantly different in patients who had LEV
withdrawn because of worsening of seizures or side
effects.
Efficacy
Two hundred and nine patients were included in the
analysis of the efficacy of LEV. At the last visit
available 70 patients (33.5%) were still treated with
LEV whereas in 139 (66.5%) patients LEV had been
stopped. The mean duration of LEV treatment in
patients with ongoing LEV therapy was 38.8 weeks
(median 33, range: 12—86 weeks) compared to 12.3
weeks (median 8, range: 0.5—75 weeks) in patients
in whom LEV had been withdrawn.
Thirteen patients became seizure free (6.2%), 39
patients had a seizure reduction of over 50%–—of
these 24 patients had a 76—99% seizure reduction
(11.5%) and 15 patients had a 50—75% seizure reduc-
tion (7.2%). Thus, in all 52 patients (24.9%) were
responders and add on LEV stopped or reduced
seizure frequency by more than 50%. In 9 of these
patients (including one seizure free patient), LEV
was discontinued because of side effects so that the
remaining 43 (20.6%) patients constitute long term
responders who continued on LEV after the last
clinical study visit.
Positive psychotropic effects were reported in 18
patients (8.6%): 15 were reported to be more bright
and alert, 2 patients had improved speech and one
patient was in a ‘better mood’ while 1 patient
showed lessening of previously observed ataxia.
In 136 patients (65.1%), seizure frequency was
neither reduced by more than 50% nor increased to
more than double of the baseline frequency. In 24 of
these patients, the therapy with LEV was continued
for more than 12 weeks and in 19 of these patients
the referring physician regarded the effect of LEVas
a ‘‘mild improvement’’ (15 patients) or ‘‘marked
improvement’’ (4 patients). The reasons to continue
LEV treatment were seizure reduction of less than
50% or seizures of shorter duration (13 patients),
fewer side effects compared to other AED (2
patients) and/or positive effect on mood and cogni-
tion (5 patients).
Fourteen of the 209 patients (6.7%) showed a
doubling of seizure frequency and in a further 7
patients an increase of seizure frequency was given
as the main reason for discontinuing LEV.
In 9 patients, the good initial response was lost
early within 4 weeks with seizure frequency return-
ing to a similar level as before treatment (4.3%) and
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Figure 1 Effect of LEV on seizure frequency (efficacy
analysis).
Figure 2 Effect of LEV on different types of seizures
(often more than one type in a single patient).similarly 28 patients (13.4%) showed delayed toler-
ance with loss of improved seizure control after
more than 4 weeks.
In seven patients (3.3%), the effect of LEV on
seizure frequency could not be evaluated because
side effects lead to a quick withdrawal of LEV in two
patients. The remaining five patients had no visible
seizures and LEV was given to reduce EEG discharges
in CSWS syndrome. None of the five showed a lasting
reduction of discharge frequency, but three showed
improvement in cognition (classified as ‘‘mild
improvement’’ in one patient and ‘‘marked
improvement’’ in two patients).
There was no difference in the outcome in differ-
ent epilepsy syndromes (p > 0.1, Fisher’s exact
test): a seizure reduction of 50% was seen in
26.1% (35/134) patients with focal epilepsy, in
18.4% (7/38) patients with generalized epilepsy
and in 33.3% (10/30) patientswith epilepsywith focal
and generalized signs. We also found no significant
differences in seizure control (p > 0.1, Fisher’s exact
test) based on etiology of the epilepsy syndrome:
29.8% (36/121) with symptomatic epilepsy, 20.0% (5/
25) patients with idiopathic epilepsy and 16.7% (9/
54) patients with cryptogenic focal epilepsy (Fig. 1).
The 12 patients who became seizure free and had
ongoing treatment (mean  S.D.: 30  15 weeks)
received average daily doses (S.D.) of 35.5 
21.5 mg/kg compared to 53.0  23.8 mg/kg/day
in all other patients with ongoing treatment.
Seizure types
The results show that the outcome was dependent
on seizure type (Kruskal—Wallis test, p = 0.004) witha most favourable outcome in secondarily general-
ized tonic seizures and simple partial seizures, fol-
lowed by generalized tonic—clonic seizures,
complex partial seizures, myoclonic and tonic sei-
zures. Improved seizure control was least likely with
absences and atonic seizure (see Fig. 2). However, as
a whole when considering the most frequent sei-
zures types (n > 40) the outcome did not differ
significantly (Kruskal—Wallis test, p = 0.439).
Discussion
Drug-resistant epilepsy remains a challenging clin-
ical issue in pediatric neurology.
New treatment paradigms that have gained
increasing prominence in optimizing patient man-
agement include early resective surgery, the keto-
genic diet and vagal nerve stimulation. A number of
new drugs have been added to the clinical reper-
toire in recent years to improve seizure control and
reduce drug-related comorbidities in the pediatric
population. Of these LEV promises to be a potent
and well-tolerated drug based on adult studies and
the first clinical pediatric studies. The group of very
drug-resistant children with high rates of coexisting
comorbidities stand to benefit from the early use of
a well-tolerated potent new drug such as LEV.
In our study, we report on the observed seizure
control and side effects in 285 pediatric patients
with drug-resistant epilepsy treated with LEVas part
of a multicenter observational survey. In this large
sample, LEV was generally well tolerated and there
were no reports of significant drug interactions and
or idiosyncratic side effects. Although side effects
were documented quite frequently (in 128 (44.9%)
patients), they were often limited to the titration
period, did not invariably lead to drug withdrawal
and were reversible on cessation of treatment.
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Mental retardation and physical handicap appeared
as a risk factor for experiencing somnolence during
LEV treatment which was seen in 25.8% of mentally
retarded patients and in only 4.5% of normal devel-
oped patients.
Behavioural changes that occurred with the intro-
duction of LEV were seen in 15.4% of our patients.
They were considered clinically relevant and dis-
turbing in some patients and led to discontinuation
of LEV treatment in 8.1% of our patients. Comparing
these data to a number of adult studies where the
incidence of aggression was no higher than with
placebo1—3 or appeared in only 9 of 118 patients
(7.6%) in a recent study of a subgroup of learning
disabled adults,5 behavioural side effects appear to
be more frequent in the pediatric patient popula-
tion. Weyrheter et al. reported of withdrawal of LEV
due to irritability and aggression in a third of 28
pediatric patients.6
Similarly, Kugler et al. reported irritability,
increased aggressiveness, mood changes and atten-
tional disturbances in 23/79 patients7 and aggres-
sive, oppositional behaviour was also observed in 36
of 115 patients in data of Gustafson et al.8 Of the
neuropsychological side effects reported in our
patients somnolence, sleep disturbances and beha-
viour disorders were most frequent in patients with
physical handicap or mental retardation so that this
patient group needs to be monitored carefully for
these adverse events under LEV treatment. As yet
there is no data available on the effects of titration
rate on these side effects or dose related issues.
The single most severe adverse event observed in
our study was an acute bout of hemorrhagic colitis in
a two-year-old girl which was rapidly reversible on
immediate drug withdrawal and has been recently
also reported in two adult cases.9
A number of pediatric studies usually on small
selected patient groups report on seizure control
with LEV.10—22 With regard to the effectiveness of
LEV in improving seizure control in this cohort of
drug-resistant epilepsy we found a 50% responder
rate in 20.6% while 6% still became seizure free. This
rate is lower than the response rates found in the
large phase III-studies with adult patients1—3 and
lower than the rates in most previous studies with
pediatric patients. Responder rates of 33.3% were
reported by Coppola 10 and up to 40—50% were
reported separately by Bourgois et al.,11 Gustafson
et al.,8 Lagae et al.,12 Nieto-Barrera,13 and Veen-
drick-Meekes et al.14 Responder rates of more than
50% have been reported by Garcia-Penˇas et al.,15
Glauser et al.,16 Herranz et al.,17 Mordekar,18 Papa-
vasiliou,19 and Tan and Appelton 20 This wide range
of response of seizure control to LEV most likelyrepresents the heterogeneous patient populations
studied showing variable effectiveness of the drug.
As LEV is a new AED, which is not yet approved for
the use in children, there is a strong selection bias
for patients with very difficult to treat epilepsies.
This bias is enhanced in our data which is made up of
pooled data of the first experiences with LEV col-
lected from 19 child neurology departments in Ger-
many.
The patients investigated in our study had highly
refractory epilepsies. They were treated with a high
number of AEDs before LEV was added on (mean: 7
AED), had a long duration of epilepsy (mean: 6.0
years) compared to theageof thepatients (9.9 years)
and were frequently mentally retarded (92.1%).
The phenomenon of increased seizure frequency
under new AED drug treatment which was seen in
10% of our patients with doubling in 6.7% of these
raises the interesting issue of idiosyncratic seizure
activation by LEV. This has also been reported by
other authors: Nakken et al.21 observed an increase
in seizure frequency in 19/44 (43%) pediatric
patients, Veendrick-Meekes et al.14 reported an
increase in seizure frequency in 5/59 (8.5%) children
and adolescents and Wannag and Ng noted what
they felt to be a dosage related increase: after an
initial good response to LEV the seizure frequency
again increased with doses of 30 mg/kg/day or
higher in 19 of 45 patients (42%).22 However, this
phenomenonmay reflect early seizure breakthrough
and therefore the natural history of the epilepsy
rather than true activation.
In addition to responder rates, the retention rate
is an important measure of the overall drug effec-
tiveness as this represents a reliable composite
measure of adverse events and efficacy over time.23
At the last visit available, 70 of the 209 patients
(33.5%) were still on medication with LEV. This
means that in addition to the 43 responders who
had a seizure reduction of more than 50%, there
were 27 other patients who continued LEV. Reasons
for this were a seizure reduction of less than 50%
which apparently still was regarded as a benefit to
the patient, seizures were of shorter duration and a
positive effect was observed onmood and cognition.
Thus, one-third of patients benefited from LEV
treatment. Prospective comparative studies will
be necessary to further elucidate these parameters
for the use of LEV in children.
Can we at this point make a general statement
about which patients should be treated with
LEV? Our data do not show any significant differ-
ences in the responder rates dependent on
epilepsy syndromes, but the responder rates differ
between seizure types. Focal seizures (simple and
complex partial, secondary generalized tonic—clo-
Levetiracetam in 285 children 483nic seizures) responded better than generalized
seizures (primary generalized tonic—clonic sei-
zures, absen- ces). This is in accordance with
the data of Wheless and Ng24 in 39 pediatric
patients.
Regarding LEV dosaging LEV was administered in
maximum dosages of 47.7  21.8 mg/kg/day in our
survey. In the 13 patients who became seizure free,
the mean dosage was lower 35.8  20.6 mg/kg/
day (range: 10—93 mg/kg/day). This reflects the
practice of increasing the daily dosage till seizure
control is achieved or the maximal tolerated dosage
is attained. Our data do not permit conclusions
about daily recommended dosages but suggest that
most treatable patients will respond in the 30—
40 mg/kg/day range.
Although our study includes a large number of
patients there are a number of limitations in our
study design. Principally these include the hetero-
geneous and highly refractory patient group with
various seizure types, epilepsy syndromes and addi-
tional neurological deficits. The study was not
designed with a set protocol defining the handling
of comedication, LEV dosages, titration schedules
and study endpoint.
Nevertheless valuable new information was
gained from the statistical analysis of the pooled
data of the largest cohort of pediatric patient
reported in a single study to date.
In conclusion, our study supports the available
data to date that LEV is an effective and well-
tolerated AED in children with refractory epilepsy.
Severe side effects were rare but patients with
additional comorbidities are more likely to have
side effects which need to be monitored. Besides
its value as a new add-on drug in resistant epilepsy,
further studies are required to determine the value
of LEV as a first line drug by defining its comparative
efficacy and tolerability over other established
AEDs.
The neurotoxic side effects observed in our study
and reported on by other authors in the literature
need to be monitored in the long-term treatment
paradigms of pediatric patients and may limit its use
in at risk subgroups of children with mental and
physical handicaps.
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